These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14626985)

  • 1. Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory.
    Blackwell AE; Beck JM;
    Food Drug Law J; 2003; 58(3):439-62. PubMed ID: 14626985
    [No Abstract]   [Full Text] [Related]  

  • 2. The Food and Drug Administration's regulation of prescription drug manufacturer speech: a First Amendment analysis.
    Evans GW; Friede AI;
    Food Drug Law J; 2003; 58(3):365-437. PubMed ID: 14626984
    [No Abstract]   [Full Text] [Related]  

  • 3. The First Amendment and the Food and Drug Administration's regulation of labeling and advertising: three proposed reforms.
    Kahan JS; Shapiro JK
    Food Drug Law J; 2003; 58(3):353-64. PubMed ID: 14626983
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: can we talk? About Food and Drug Regulation and the First Amendment.
    Cohen MN
    Food Drug Law J; 2003; 58(4):741-56. PubMed ID: 15027458
    [No Abstract]   [Full Text] [Related]  

  • 5. Education or promotion?: Industry-sponsored continuing medical education (CME) as a center for the core/commercial speech debate.
    Chen P;
    Food Drug Law J; 2003; 58(3):473-509. PubMed ID: 14626981
    [No Abstract]   [Full Text] [Related]  

  • 6. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 7. A global view of the First Amendment constraints of FDA.
    Carver KH
    Food Drug Law J; 2008; 63(1):151-215. PubMed ID: 18561459
    [No Abstract]   [Full Text] [Related]  

  • 8. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 10. In Opposition to Liberty: We Need a "Sovereign" to Govern Drug Claims.
    Avorn J
    Ann Intern Med; 2015 Aug; 163(3):229-30. PubMed ID: 26121615
    [No Abstract]   [Full Text] [Related]  

  • 11. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 13. The First Amendment and federal court deference to the Food and Drug Administration: The Times They Are A-Changin'.
    Basile EM; Gross M
    Food Drug Law J; 2004; 59(1):31-44. PubMed ID: 15190924
    [No Abstract]   [Full Text] [Related]  

  • 14. Caveat doctor.
    McCarthy M
    Lancet; 1999 Aug; 354(9177):446. PubMed ID: 10465167
    [No Abstract]   [Full Text] [Related]  

  • 15. Ripe for revision: reassessing the constitutionality of Food and Drug Administration restrictions on protected speech.
    Gibbs JN; Ferrari PL; Murphy AM;
    Food Drug Law J; 2003; 58(3):331-45. PubMed ID: 14626233
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 17. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 18. The new drug marketing: a consumer protection perspective.
    Woodward D
    Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA's graphic tobacco warnings and the first amendment.
    Orentlicher D
    N Engl J Med; 2013 Jul; 369(3):204-6. PubMed ID: 23803137
    [No Abstract]   [Full Text] [Related]  

  • 20. The ongoing dialogue between the Food and Drug Administration and the Federal Trade Commission.
    Leary TB
    Food Drug Law J; 2004; 59(2):209-15. PubMed ID: 15318392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.